Mycophenalate Mofetil as a corticosteroid- sparing agent in patients with sarcoidosis.

Conclusion: This study indicates that MMF can be used as CS sparing agent allowing a significant reduction of maintenance corticosteroids dose to <10mg/day, with improved clinical condition in patients with sarcoidosis.

Source: European Respiratory Journal - November 19, 2018 Category: Respiratory Medicine Authors: Stagaki, E., Manali, E. D., Papadaki, G., Papaioannou, A. I., Korbilla, I., Papaporfyriou, A., Giouleka, A., Kallieri, M., Kolilekas, L., Triantafyllidou, C., Papiris, S. Tags: Clinical Problems Source Type: research